Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized medicine for kidney disease: can genes predict who will respond?

NCT ID NCT07416942

Knowledge-focused Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find genetic and protein markers that can predict whether patients with membranous nephropathy, a kidney disease, will respond to the drug rituximab. Researchers will analyze stored blood and tissue samples from 120 patients and healthy volunteers. The goal is to develop a personalized approach to treatment, avoiding ineffective therapies and their side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors choose the right treatment for membranous nephropathy patients, improving outcomes and reducing side effects.
What could go wrong
This is an observational study on stored samples, not a treatment trial. The findings may not lead to immediate clinical changes or may not be confirmed in future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient biological samples. The study will use samples collected from patients of the PROMENADE Study (NCT06242327) with a histologically confirmed diagnosis of MN, and who were treated with RTX. The samples, collected before and after RTX treatment, include DNA (n=300), sera (n=120), and peripheral blood mononuclear cells (PBMCs) (n=65), and are stored at the biobank of one of the IRFMN's site, the Clinical Research Center for Rare Diseases Aldo e Cele Daccò. Healthy volunteers: for comparison reasons, 60 volunteers, matched for age and sex, will also be analyzed.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patients Inclusion Criteria: * Adult patients * Biopsy-proven primary membranous nephropathy (MN) * Written informed consent for storage of biological samples in the local biobank Exclusion Criteria: * Absence of signed written informed consent for the storage of samples in the biobank Healthy subjects Inclusion Criteria: * Adult male and female * Written informed consent Exclusion Criteria: * History of renal diseases, autoimmune disorders, diabetes mellitus, current allergies * Subjects who have taken antibiotics, anti-inflammatory drugs, or antihistamines within the past 7 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Membranous nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Membranous nephropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Research Centre for Rare Diseases Aldo e Cele Daccò

    Ranica, BG, 24020, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.